Geographical Expansion
Expected: March 2026HIGH confidence
What: acquisition_value: ₹77 Cr
Impact: Entry into Ahmedabad market
Gujarat Kidney & Super Speciality Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +26.9%Weak6w Streak
In , Gujarat Kidney & Super Speciality Ltd (Hospitals/Medical Services) is outperforming Nifty 500 with +26.9% relative strength. Fundamentals: Weak. On a 6-week streak.
Gujarat Kidney & Super Speciality Ltd Key Facts
- PE Ratio
- 100.0x
- Market Cap
- ₹987 Cr
- PAT Growth YoY
- +46%
- Revenue Growth YoY
- +97%
- OPM
- 29.7%
- RS vs Nifty 500
- +26.9%
What's Happening
📊Debt increased 135% YoY — leverage rising
🌐FII stake decreased 5.6% this quarter
🏛️DII reducing — stake down 1.1%
💰Trading 57% above estimated fair value — significant premium
Earnings Acceleration Triggers
1. Geographical Expansion
March 2026HIGH
2. Operating Leverage Inflection
FY26MEDIUM
Key Risks
1. Fined ₹6
MEDIUM2. 100% of operations are concentrated in Gujarat, making the business vulnerable t
MEDIUMSector-Specific Signals
Operational Bed Capacity340 beds
Average Revenue Per Occupied Bed₹11,243
Bed Occupancy Rate54.77%
Average Revenue Per Inpatient₹67,458
Key Numbers
PAT Growth YoY
+46%
Insufficient Data
Revenue YoY
+97%
Insufficient Data
Operating Margin
29.7%
-934 bps YoY
PE Ratio
100.0
Current Price
₹125
Fundamental Score
38/100
Weak
3Y PAT CAGR
+80%
Market Cap
1.1K Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
Why Are Gujarat Kidney & Super Speciality Ltd's Earnings Accelerating?
Based on Q3 FY26 (web) earnings • Updated Apr 18, 2026
Operating Leverage Inflection
Expected: FY26MEDIUM confidence
What: ebitda_growth: 33.59% QoQ
What Are the Key Risks for Gujarat Kidney & Super Speciality Ltd?
Earnings deceleration risks from management commentary
Fined ₹6
MEDIUMTrigger: Fined ₹6.61 Lakh by NSE/BSE for delayed financial results and ₹20,000 for board meeting intimation delays.
Impact: PAT impact: ₹0.06 Cr
Management view: Appointed new secretarial and internal auditors; ratified prior board actions to strengthen compliance.
Monitor: regulatory
100% of operations are concentrated in Gujarat, making the business vulnerable t
MEDIUMTrigger: 100% of operations are concentrated in Gujarat, making the business vulnerable to regional economic or political changes.
Management view: Expanding into new cities like Ahmedabad and Bharuch to diversify regional footprint.
Monitor: geopolitical
What Did Gujarat Kidney & Super Speciality Ltd Report This Quarter?
Headline numbers from the latest earnings call
Revenue
₹23.31 Cr
YoY +96.9%QoQ +79%
Revenue growth was driven by a 96.9% YoY surge in consolidated income following the company's listing and operational scaling.
EBITDA
₹6.96 Cr
Margin 29.85%
EBITDA grew 33.59% QoQ, though margins were pressured by a 103.3% QoQ increase in total expenses.
PAT
₹3.70 Cr
YoY +46.2%QoQ +28.5%
Net profit growth lagged revenue growth due to a sharp rise in operating expenses and finance costs.
Other Highlights
• Consolidated expenses rose 121.6% YoY to ₹18.28 Cr
• EPS for Q3FY26 stood at ₹0.52
• Standalone revenue grew 14.79% YoY to ₹9.76 Cr
What Sector Metrics Matter for Gujarat Kidney & Super Speciality Ltd?
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Operational Bed Capacity
340 beds
Why: Not explained in source
Average Revenue Per Occupied Bed
₹11,243
Why: Not explained in source
Bed Occupancy Rate
54.77%
Why: Not explained in source
Average Revenue Per Inpatient
₹67,458
Why: Not explained in source
Self-Pay Revenue Contribution
80.64%
Why: Not explained in source
Debtor Days
138 days
YoY Improved from 229 days
Why: Not explained in source
What Is Gujarat Kidney & Super Speciality Ltd's Management Guidance?
Forward-looking targets from management
Capex Plan
₹30.09 Cr
Capex Plan
₹30.09 Cr
Funding capital expenditure requirements for a new hospital in Vadodara
Management Tone: CAUTIOUS
How Fast Is Gujarat Kidney & Super Speciality Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +97% | — | Insufficient Data |
| PAT (Net Profit) | +46% | +80% | Insufficient Data |
| OPM | 29.7% | -934 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Other Top Hospitals/Medical Services Stocks Beating Nifty 500
Frequently Asked Questions: Gujarat Kidney & Super Speciality Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Gujarat Kidney & Super Speciality Ltd's latest quarterly results?
Gujarat Kidney & Super Speciality Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +46.2% (insufficient_data)
- Revenue Growth YoY: +97.2%
- Operating Margin: 29.7% (volatile)
Is Gujarat Kidney & Super Speciality Ltd's profit growing or declining?
Gujarat Kidney & Super Speciality Ltd's profit is growing with an insufficient_data trend.
- PAT Growth YoY: +46.2% (latest quarter)
- PAT Growth QoQ: +28.5% (sequential)
- 3-Year PAT CAGR: +80.0%
- Trend: Insufficient_data — consistent growth pattern
What is Gujarat Kidney & Super Speciality Ltd's revenue growth trend?
Gujarat Kidney & Super Speciality Ltd's revenue growth trend is insufficient_data.
- Revenue Growth YoY: +97.2%
- Revenue Growth QoQ: +79.8% (sequential)
How is Gujarat Kidney & Super Speciality Ltd's operating margin trending?
Gujarat Kidney & Super Speciality Ltd's operating margin is volatile.
- Current OPM: 29.7%
- OPM Change YoY: -9.3% basis points
- OPM Change QoQ: -9.9% basis points
What is Gujarat Kidney & Super Speciality Ltd's 3-year profit and revenue CAGR?
Gujarat Kidney & Super Speciality Ltd's long-term compounding rates
- 3-Year Profit CAGR: +80.0%
Is Gujarat Kidney & Super Speciality Ltd's growth accelerating or decelerating?
Gujarat Kidney & Super Speciality Ltd's earnings growth is insufficient_data with mixed signals on a sequential basis.
- YoY Acceleration: +48.9% bps
- Sequential Acceleration: +75.2% bps
- Margin Warning: Operating margins are under pressure
Is Gujarat Kidney & Super Speciality Ltd overvalued or undervalued?
Gujarat Kidney & Super Speciality Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Current PE: 100.0x
- Price-to-Book: 29.4x
What is Gujarat Kidney & Super Speciality Ltd's current PE ratio?
Gujarat Kidney & Super Speciality Ltd's current PE ratio is 100.0x.
- Current PE: 100.0x
- Market Cap: 987 Cr
How does Gujarat Kidney & Super Speciality Ltd's valuation compare to its history?
Gujarat Kidney & Super Speciality Ltd's current PE is 100.0x.
- Current PE: 100.0x
- Valuation Assessment: Significantly Overvalued
What is Gujarat Kidney & Super Speciality Ltd's price-to-book ratio?
Gujarat Kidney & Super Speciality Ltd's price-to-book ratio is 29.4x.
- Price-to-Book (P/B): 29.4x
- Book Value per Share: ₹4
- Current Price: ₹125
Is Gujarat Kidney & Super Speciality Ltd a fundamentally strong company?
Gujarat Kidney & Super Speciality Ltd is rated Weak with a fundamental score of 38/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +97.2% (10% weight)
- PAT Growth YoY: +46.2% (10% weight)
- PAT Growth QoQ: +28.5% (10% weight)
- Margins stable (10% weight)
Is Gujarat Kidney & Super Speciality Ltd debt free?
Gujarat Kidney & Super Speciality Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹20 Cr
What is Gujarat Kidney & Super Speciality Ltd's return on equity (ROE) and ROCE?
Gujarat Kidney & Super Speciality Ltd's return ratios over recent years
- FY2024: ROCE 19.3%
- FY2025: ROCE 51.5%
Is Gujarat Kidney & Super Speciality Ltd's cash flow positive?
Gujarat Kidney & Super Speciality Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹14 Cr
- Free Cash Flow (FCF): ₹-5 Cr
- CFO/PAT Ratio: 143% (strong cash conversion)
What is Gujarat Kidney & Super Speciality Ltd's dividend yield?
Gujarat Kidney & Super Speciality Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹125
Who holds Gujarat Kidney & Super Speciality Ltd shares — promoters, FII, DII?
Gujarat Kidney & Super Speciality Ltd's shareholding pattern (Mar 2026)
- Promoters: 71.5%
- FII (Foreign): 4.9%
- DII (Domestic): 0.6%
- Public: 23.1%
Is promoter holding increasing or decreasing in Gujarat Kidney & Super Speciality Ltd?
Gujarat Kidney & Super Speciality Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 71.5% (Mar 2026)
- Previous Quarter: 71.5% (Dec 2025)
- Change: 0.00% (stable)
How long has Gujarat Kidney & Super Speciality Ltd been outperforming Nifty 500?
Gujarat Kidney & Super Speciality Ltd has been outperforming Nifty 500 for 6 consecutive weeks, indicating building momentum.
Is Gujarat Kidney & Super Speciality Ltd a new momentum entry or an established outperformer?
Gujarat Kidney & Super Speciality Ltd is an established outperformer with 6 weeks of consecutive Nifty 500 outperformance.
What are the growth catalysts for Gujarat Kidney & Super Speciality Ltd?
Gujarat Kidney & Super Speciality Ltd has 2 key growth catalysts identified from recent earnings analysis
- Geographical Expansion — Parekhs Hospital adds ₹25.67 Cr in revenue, representing a >50% increase over the company's FY25 consolidated revenue.
- Operating Leverage Inflection — Scaling operations is driving EBITDA growth, though high expense growth currently offsets margin expansion.
What are the key risks in Gujarat Kidney & Super Speciality Ltd?
Gujarat Kidney & Super Speciality Ltd has 2 key risks worth monitoring
- [MEDIUM] Fined ₹6 — Fined ₹6.61 Lakh by NSE/BSE for delayed financial results and ₹20,000 for board meeting intimation delays.
- [MEDIUM] 100% of operations are concentrated in Gujarat, making the business vulnerable t — 100% of operations are concentrated in Gujarat, making the business vulnerable to regional economic or political changes.
What is Gujarat Kidney & Super Speciality Ltd's management guidance for growth?
Gujarat Kidney & Super Speciality Ltd's management has provided the following forward guidance
- Revenue outlook: Not Given
- Margin outlook: Not Given
- Capex plan: ₹30.09 Cr for Funding capital expenditure requirements for a new hospital in Vadodara
- Management tone: cautious
What sector-specific metrics matter most for Gujarat Kidney & Super Speciality Ltd?
Gujarat Kidney & Super Speciality Ltd's most important sub-sector-specific KPIs from the latest concall
- Operational Bed Capacity: 340 beds — Not explained in source
- Average Revenue Per Occupied Bed: ₹11,243 — Not explained in source
- Bed Occupancy Rate: 54.77% — Not explained in source
- Average Revenue Per Inpatient: ₹67,458 — Not explained in source
- Self-Pay Revenue Contribution: 80.64% — Not explained in source
- Debtor Days: 138 days (YoY Improved from 229 days) — Not explained in source
Is Gujarat Kidney & Super Speciality Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Gujarat Kidney & Super Speciality Ltd may be worth studying
- Earnings growing at +46.2% YoY
- Cash flow is positive — CFO ₹14 Cr
What is the investment thesis for Gujarat Kidney & Super Speciality Ltd?
Gujarat Kidney & Super Speciality Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +97.2% YoY
- Growth catalyst: Geographical Expansion
Risk Factors (Bear Case)
- Margins under pressure
- Appears significantly overvalued
- Key risk: Fined ₹6
What is the future outlook for Gujarat Kidney & Super Speciality Ltd?
Gujarat Kidney & Super Speciality Ltd's forward outlook based on current data signals
- Earnings Trend: insufficient_data
- Revenue Trend: insufficient_data
- Margin Trend: volatile
- Valuation: Significantly Overvalued
- Key Catalyst: Geographical Expansion
- Key Risk: Fined ₹6
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.